

## Léčba povrchového karcinomu močového měchýře z přechodného epitelu: kritické zhodnocení současných postupů a budoucí perspektivy

THOMAS-ALEXANDER VÖGELI

Department of Urology, Medical Centre Aachen, Germany

### LITERATURA

- 1 Feldmann AR, Kessler L, Myers MH. The prevalence of cancer. *N Engl J Med* 1996; 315: 1394–7
- 2 Pyrah LN, Raper FP, Thomas GM. Report of a follow up of papillary tumours of the bladder. *Br J Med* 1964; 36: 14–25
- 3 Eble JN, Sauter G, Epstein JI, Sesterhenn IA eds. *Pathology and Genetics of Tumors of the Urinary System and Male Genital Organs*. Lyon: IARC Press, 2004
- 4 Malmstrom PU, Busch C, Norlen BJ. Recurrence, progression and survival in bladder cancer. A retrospective analysis of 232 patients with greater than or equal to 5-year follow up. *Scand J Urol Nephrol* 1987; 21: 185–95
- 5 Cheng L, Neumann RM, Bostwick DG. Papillary urothelial neoplasms of low malignant potential. Clinical and biological implications. *Cancer* 1999; 86: 2102–8
- 6 Alsheik A, Mohamedali Z, Jones E, Materson J, Gilks CB. Comparison of the WHO ISUP classification and cytokeratin 20 expression in predicting the behavior of low grade papillary urothelial lesions. *Mod Pathol* 2001; 14: 267–72
- 7 Holmang S, Andius P, Hedelin H, Wester K, Busch C, Johannson SL. Stage progression in Ta papillary urothelial tumors. Relationship to grade, immunohistochemical expression of tumor markers, mitotic frequency and DNA ploidy. *J Urol* 2001; 165: 1124–8
- 8 Meijeden A, Sylvester R, Colette L, Bono A, Ten Kate F. The role and impact of pathology review on stage and grade assessment of stages Ta and T1 bladder tumors: a combined analysis of 5 EORTC trials. *J Urol* 2000; 164: 1533–7
- 9 Pathologist of the French Association of Urology Cancer Committee. Lamina propria microinvasion of bladder tumors, incidence or stage allocation (pTa vs PpT1): recommended approach. *World J Urol* 1993; 11: 161–4
- 10 Witjes JA, Kiemeny LA, Schaffma HE, Debruyne FM. The influence of review pathology on study outcome of a randomized multicentre superficial bladder cancer trial. *Br J Urol* 1994; 73: 172–6
- 11 Tosoni I, Wagner U, Sauter G, Egloff M, Nönagel H, Alund G. Clinical significance of interobserver differences in the staging and grading of superficial bladder cancer. *BJU Int* 2000; 85: 48–53
- 12 Milner WA. Results in the treatment of bladder tumors. *J Urol* 1953; 69: 657–64
- 13 Bressel M, Kemper K. Vorbedingungen und Technik der transurethralen Resektion. *Urologe A* 1969; 8: 73–80
- 14 Marberger A, Marberger F, DeCristoforo A. The current status of transurethral resection in the diagnosis and therapy of carcinoma of the urinary bladder. *Int Urol Nephrol* 1972; 4 : 35–44
- 15 Flamm J, Steiner R. Stellenwert der differenzierten transurethralen Resektion beim primären oberflächlichen Harnblasenkarzinom. *Urologe A* 1991; 30: 111–3
- 16 Koloscy Z. Histopathological self control in transurethral resection of bladder tumours. *Br J Urol* 1976; 116: 575–80
- 17 Klän R, Loy V, Huland H. Residual tumor discovered in routine second transurethral resection in patients with stage T1 transitional cell carcinoma of the bladder. *J Urol* 1991; 46: 316–8
- 18 Köhrmann KU, Woeste M, Kappers JH, Rassweiler J, Alken P. Der Wert der transurethralen Nachresektion beim oberflächlichen Harnblasenkarzinom. *Akt Urol* 1994; 25: 208–13
- 19 Vögeli TA, Marx G, Ackermann R. Zur Notwendigkeit der Nachresektion beim oberflächlichen Blasenkarzinom als Kontrolle der Erstresektion. *Urologe A* 1991; 31: 59
- 20 Schwaibold HE, Treiber U, Kuebler H, Leyh H, Hartung R. Second transurethral resection detects histopathological changes worsening the prognosis in 25% of patients with T1 bladder cancer. *J Urol* 2000; 163: 153–4

- 21 Zurkirchen MA, Sulser T, Hauri D. Can a second resection be omitted in the treatment of bladder cancer. *Eur Urol* 2001; 39 (Suppl.): 119
- 22 Schips L, Augustin H, Zigeuner R, Trummer H, Pummer K, Hubmer G. Is a second transurethral resection justified in patients with newly diagnosed superficial bladder cancer. *Eur Urol* 2000; 37 (Suppl.): 111
- 23 Brausi M, Colette L, Kurth KH, van der Meijden AP, Oosterlinck W, Witjes JA. Variability in recurrence rate after first follow up cystoscopy after TUR in stage TaT1 transitional cell carcinoma of the bladder: a combined analysis of 7 EORTC studies. *Eur Urol* 2002; 41: 523–31
- 24 Brausi M, Sylvester R, van der Meijden A, Kurth KH. Does the surgeon have impact on the outcome of patients with Ta- T1 TCC of the bladder. *Eur Urol* 2001; 39 (Suppl.): 466
- 25 Grimm MO, Steinhoff C, Simon X, Spiegelhalder P, Ackermann R, Vögeli TA. Effect of routine transurethral resection for superficial bladder cancer: a long term observational study. *J Urol* 2003; 170: 433–7
- 26 Fitzpatrick JM, West AB, Butler MR, Lane V, O'Flynn JD. Superficial bladder tumors: the importance pattern following initial resection. *J Urol* 1986; 135: 920–4
- 27 Smith JA, Labasky RF, Ciocchetti ATK, Fracchia JA, Montie JE, Rowland RG. Bladder cancer clinical guidelines panel summary report on the management of nonmuscle invasive bladder cancer (stages Ta,T1 and Tis). *J Urol* 1999; 162: 1697–701
- 28 MRC Working Party on Urological Cancer. The effect of intravesical thiotepa on the recurrence rate of newly diagnosed superficial bladder cancer. *Br J Urol* 1985; 57: 680–3
- 29 Tolley DA, Hargreave TB, Smith PH, Williams JL, Parmar MK. Effect of intravesical mitomycin on recurrence of newly diagnosed superficial bladder cancer; interim report from the MRC Subgroup on Superficial Bladder Cancer (Urological Cancer Working Party). *Br Med J* 1988; 296: 1759–63
- 30 Oosterlinck W, Kurth KH, Schroeder FH, Bultinck J, Hammond B, Sylvester R. A prospective European Organization for Research and Treatment of Cancer Genitourinary Group randomized trial comparing transurethral resection followed by a single intravesical instillation of epirubicin or water in single stage Ta,T1 transitional cell bladder tumors: a prospective, randomized controlled study. *J Urol* 1993; 149: 749–52
- 31 Ali el Denein B, Nabeeh A, el-Baz M, Shamaa S, Ashamallah A. Single dose versus multiple instillations of epirubicin as prophylaxis for recurrence after transurethral resection of pTa and pT1 transitional cell bladder tumours: a prospective, randomized controlled study. *Br J Urol* 1997; 79: 731–4
- 32 Solsona E, Iborra I, Ricos J, Monros JL, Casanova J, Dumont R. Effectiveness of a single immediate mitomycin C instillation in patients with low risk superficial bladder cancer: short and long term follow up. *J Urol* 1999; 161: 1120–3
- 33 Rajala P, Liukkonen T, Raitanen M, Rintala E, Kaasinen E, Helle M. Transurethral resection with perioperative instillation on interferon alpha or epirubicin for the prophylaxis of recurrent primary superficial bladder cancer: a prospective randomized multicenter study - FinnBladder III. *J Urol* 1999; 161: 1133–5
- 34 Rajala P, Kaasinen E, Raitanen M, Liukkonen T, Rintala E and the FinnBladder Group. Perioperative single dose instillation of epirubicin or interferon alpha after transurethral resection for the prophylaxis of primary superficial bladder cancer recurrence: a prospective randomized multicenter study – FinnBladder III long term results. *J Urol* 2002; 168: 981–5
- 35 Okamura K, Ono Y, Kinukawa T, Matsuura O, Yamada S, Ando T. Randomized study of single early instillation of 1'R-4'-Otetrahydropyranil-doxorubicin for single superficial bladder carcinoma. *Cancer* 2002; 94: 2363–8
- 36 Sylvester RJ, Oosterlinck W, van der Meijden A. A single postoperative instillation of chemotherapy decrease the risk of recurrence in patients with stage Ta T1 bladder cancer: a meta analysis of published results of randomized clinical trials. *J Urol* 2004; 171: 2186–90
- 37 Oosterlinck W, Lobel B, Jakse G, Malmstrom PU, Stöckle M, Sternberg C. Guidelines on bladder cancer. *Eur Urol* 2002; 41: 105–12
- 38 Zaak D, Hungerhuber E, Reich O *et al.* Detection of bladder cancer with 5-ALA – results of 1713 fluorescence endoscopies. *Eur Urol* 2004; 43 (Suppl): 95
- 39 Daniltschenko D, Riedl C, Koenig F, Daha LK, Sachs M, Schnorr D. der Stellenwert der ALA (5-Aminolaevulinsäure) Fluoreszenzdetektion für die. Prognose des Oberflächlichen Blasenkarzinoms. *Aktuel Urol* 2004; 35: 497–501
- 40 Sachs MD, Daniltschenko D, Riedl CR *et al.* Fluorescence detection with 5- aminolevulinic

- acid reduces the risk of tumor recurrence and progression in patients with superficial bladder cancer: 5 year results of a prospective randomized trial. *J Urol* 2005; 173 (Suppl.): 921
- 41 Schmidbauer J, Witjes F, Schmeller N, Donat R, Susani M, Marberger M and the Hexvix PCB301/01 Study Group. Improved detection of urothelial carcinoma in situ with hexaminolevulinate fluorescence cystoscopy. *J Urol* 2004; 171: 135–8
- 42 Vögeli TA, Ackermann R. When does superficial bladder cancer resist intravesical therapy? *Semin Urol* 1990; 8: 248–53
- 43 Huncharek M, McGarry R, Kupelnick B. Impact of intravesical chemotherapy on recurrence rate of superficial transitional cell carcinoma of the bladder: results of a meta analysis. *Anticancer Res* 2001; 21: 765–80
- 44 Shelley MD, Court JB, Kynaston H, Wilt TJ, Coles B, Mason M. Intravesical bacillus Calmette Guerin versus mitomycin for TA and T1 bladder cancer. *Cochrane Library* 2003; Issue 3: Oxford: Update Software
- 45 Pawinski A, Sylvester R, Kurth KH *et al.* Combined analysis of European Organisation for Research and Treatment of Cancer and Medical Research Council randomized clinical trials for the prophylactic treatment of stage TaT1 bladder cancer. EORTC Cooperative Group and MRC Working Party on Superficial Bladder Cancer. *J Urol* 1996; 156: 1934–7
- 46 Kurth KH, Denis L, Bouffieux R *et al.* Factors affecting recurrence and progression in superficial bladder cancer. *Eur J Cancer* 1995; 31A: 1840–6
- 47 Millan-Rodriguez G, Chechile-Tomiolo G, Salvador-Bayarri J, Palou J, Algaba F, Vicente-Rodriguez J. Primary superficial bladder cancer risk groups according to progression, mortality and recurrence. *J Urol* 2000; 164: 680–4
- 48 Solsona E, Iborra I, Dumont J, Rubio-Briones J, Casanova J, Almenar S. The 3 month clinical response to intravesical therapy as a predictive factor for progression in patients with high risk superficial bladder cancer. *J Urol* 2000; 164: 685–9
- 49 Dugon F, Williamson P. Molecular markers for predicting recurrence and outcome of bladder cancer (Do the poster boys need more poster?). *Curr Opin Urol* 2004; 14: 277–849
- 50 Modlich O, Prisack B, Ramp U *et al.* Identifying superficial, muscle invasive and metastasising transitional cell carcinoma of the bladder: Use of cDNA array analysis of gene expression profiling. *Clin Cancer Res* 2004; 10: 10–4

**Korespondence:**

Thomas-Alexander Vögeli,  
Department of Urology, Medical  
Center Aachen, Aachen, Germany.  
e-mail: [Drvoegeli@aol.com](mailto:Drvoegeli@aol.com)

**Zkratky:**

TURBT, transurethral resection of bladder tumour; CIS, carcinoma *in situ*; PUNLMP, papillary urothelial neoplasm with low malignant potential; EORTC, European Organisation for Research and Treatment of Cancer; MRC, Medical Research Council; ALA, 5-aminolaevulinic acid.